O-GlcNAcase Fragment Discovery with Fluorescence Polarimetry.
Vladimir S BorodkinKarim RafieNithya SelvanTonia AristotelousIva NavratilovaAndrew T FerenbachDaan M F van AaltenPublished in: ACS chemical biology (2018)
The attachment of the sugar N-acetyl-D-glucosamine (GlcNAc) to specific serine and threonine residues on proteins is referred to as protein O-GlcNAcylation. O-GlcNAc transferase (OGT) is the enzyme responsible for carrying out the modification, while O-GlcNAcase (OGA) reverses it. Protein O-GlcNAcylation has been implicated in a wide range of cellular processes including transcription, proteostasis, and stress response. Dysregulation of O-GlcNAc has been linked to diabetes, cancer, and neurodegenerative and cardiovascular disease. OGA has been proposed to be a drug target for the treatment of Alzheimer's and cardiovascular disease given that increased O-GlcNAc levels appear to exert a protective effect. The search for specific, potent, and drug-like OGA inhibitors with bioavailability in the brain is therefore a field of active research, requiring orthogonal high-throughput assay platforms. Here, we describe the synthesis of a novel probe for use in a fluorescence polarization based assay for the discovery of inhibitors of OGA. We show that the probe is suitable for use with both human OGA, as well as the orthologous bacterial counterpart from Clostridium perfringens, CpOGA, and the lysosomal hexosaminidases HexA/B. We structurally characterize CpOGA in complex with a ligand identified from a fragment library screen using this assay. The versatile synthesis procedure could be adapted for making fluorescent probes for the assay of other glycoside hydrolases.
Keyphrases
- high throughput
- cardiovascular disease
- living cells
- single molecule
- single cell
- quantum dots
- type diabetes
- small molecule
- endothelial cells
- protein protein
- transcription factor
- emergency department
- amino acid
- papillary thyroid
- cardiovascular risk factors
- metabolic syndrome
- young adults
- binding protein
- cardiovascular events
- cognitive decline
- insulin resistance
- skeletal muscle
- replacement therapy
- glycemic control
- resting state
- electronic health record